Slide 1: Recursion Earnings Call
Recurs ion. Learnings) Call
Slide 2: Important Information
Important Information This presentation of Recursion Pharmaceuticals, Inc. (“Recursion,” “we,” “us,” or “our”) and any accompanying discussion contain statements that are not historical facts may be considered forward-looking statements under federal securities laws and may be identified by words su
Slide 3: Important Information (continued)
Important Information (continued) Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the company’s own internal estimates and research. While the company believes these third-party sources t
Slide 4: Recursion and Exscientia Combination
Recursion and Exscientia Combination 4
Slide 5: Recursion enters agreement with Exscientia
Recursion enters agreement with Exscientia to bring better medicines to patients more rapidly and more cost efficiently Combination of Many Complementary Factors • Pipeline: Diverse portfolio of clinical and near-clinical programs with ~10 clinical readouts over the next ~18 months • Partnerships: D
Slide 6: Recursion + Exscientia: Pipeline
Recursion + Exscientia: Pipeline • Diverse Portfolio of clinical or near-clinical programs ~10 clinical readouts in the next 18 months • ~10 clinical readouts over the next ~18 months • Complementary therapeutic pipelines with no competitive overlap Combining first-in-class and best- • Most of these
Slide 7: Recursion + Exscientia: Pipeline of technology-enabled programs
Recursion + Exscientia: Pipeline of more than 10 technology-enabled programs demonstrate maturity and de-risking Anticipated Near- Program Indication Target Preclinical Phase 1 Phase 2 Phase 3 Term Milestones Topline readout Sep. 2024 REC-994 Cerebral Cavernous Malformation Superoxide SYCAMORE Preli
Slide 8: Recursion + Exscientia: Partnerships
Recursion + Exscientia: Partnerships • Diverse Portfolio of transformational partnerships with leading large pharma companies • 10 programs already optioned across oncology and immunology • Combined company expects potential additional milestone payments of ~$200 million over the next 2 years from c
Slide 9: Recursion + Exscientia: Platform
Recursion + Exscientia: Platform • Core Strengths • Recursion: scaled biology exploration and translational capabilities primarily focused on first-in- disease opportunities • Exscientia: precision chemistry design and small molecule automated synthesis primarily focused on best-in-class opportuniti
Slide 10: Exscientia capabilities integrating with the Recursion OS
Overview of areas where Exscientia’s capabilities can immediately integrate and complement the Recursion OS upon close Complementary capabilities through combination with Exscientia labelled in orange. 10
Slide 11: Recursion + Exscientia: Summary of complementary factors
Recursion + Exscientia: Summary of complementary factors Scaled exploration and mapping of Precision chemistry design and Platform Strength biological relationships molecular synthesis First-in-class products in oncology, Best-in-class products in oncology, Internal Pipeline rare disease, infectious
Slide 12: Transaction details of Recursion-Exscientia combination
Transaction details of Recursion-Exscientia combination • Stock for stock transaction Stock • Exscientia shareholders will receive 0.7729 shares of Recursion Class A common Consideration stock for each Exscientia ordinary share, subject to rounding for fractional shares Pro-Forma • Recursion shareho
Slide 13: Exscientia: '617 precision designed to have best-in-class properties
Exscientia: ‘617 precision designed to have best-in-class properties Maximize upside potential of precision- Precision designed to maximize therapeutic index allowing for designed GTAEXS617 with purchase of full optimized combinations and potentially better efficacy rights from GT Apeiron: • Selecti
Slide 14: Business Developments and Potential Milestones
Recursion Business Developments and Potential Milestones 14
Slide 15: Roche-Genentech Optioned Neuroscience Phenomap for $30 Million
Roche-Genentech Optioned Industry-First Neuroscience Phenomap from Recursion for $30 Million $30 million is part of a fee structure that could exceed a total of $500 million Fee across multiple maps, not inclusive of program milestones Structure Validates Recursion’s scientific approach to mapping b
Slide 16: Delivering value across partnership with Bayer in undruggable oncology
Recursion is delivering value across its partnership with Bayer in undruggable oncology On track to complete 25 unique multi-modal data packages in Q3 Work initiated Nov 2023 Focus on Oncology Q1 Q2 Q3 Bayer is the 1st beta-user Initiated 1st Joint Project which is of LOWE (Recursion’s LLM advancing
Slide 17: Clinical: CCM REC-994 Topline Readout in September 2024
Clinical: CCM REC-994 for CCM : Topline Readout in September 2024 SYCAMORE is the first industry-sponsored Phase 2 trial for CCM Disease & Unmet Need REC-994 Phase 2 • Cerebral Cavernous Malformation (CCM) affects ~360,000 symptomatic patients in the US and EU5 SYCAMORE Randomized, double-blind, • L
Slide 18: Milestones: Pipeline – Clinical Trial Readouts Expected in ~18 Months
Milestones: Pipeline – 7 Clinical Trial Readouts Expected in ~18 Months Pipeline • CCM: Ph2 readout expected in September 2024 • NF2: Ph2 safety & preliminary efficacy expected in Q4 2024 • FAP: Ph2 safety & preliminary efficacy expected in H1 2025 • AXIN1 or APC Mutant Cancers: Ph2 safety & prelimi
Slide 19: Milestones: Partnerships and Platform
Milestones: Partnerships and Platform Partnerships Platform • Roche & Genentech: validation program option exercised for • Built our 1st genome-scale transcriptomics KO map, 1st validated hit series in oncology, 1st neuroscience moving towards multiomics foundation models phenomap optioned for $30M
Slide 20: Earnings Call
Recursion. Learnings) Call